第三届董事会第十六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：688161 证券简称：威高骨科 公告编号：2025-042 山东威高骨科材料股份有限公司 一、董事会会议召开情况 山东威高骨科材料股份有限公司（以下简称"公司"）第三届董事会第十六 次会议于 2025 年 10 月 29 日以现场及通讯相结合的方式召开。本次会议应出席 董事 9 人，实际出席董事 9 人，会议由董事长陈敏女士主持，本次董事会会议的 召集和召开程序符合有关法律、行政法规、部门规章、规范性文件和《公司章程》 的规定，会议决议合法、有效。 二、董事会会议审议情况 1、审议通过《关于公司<2025 年第三季度报告>的议案》 公司董事会认为：公司《2025 年第三季度报告》的编制和审议程序符合法 律、法规、《公司章程》和公司内部管理制度的各项规定；公司《2025 年第三季 度报告》的内容与格式符合中国证券监督管理委员会和上海证券交易所的各项规 定，能够公允地反映公司报告期内的财务状况和经营成果。董事会及全体董事保 证公司《202 ...

Financial Performance - The company's operating revenue for Q3 2025 was CNY 365,344,702.03, representing a year-on-year increase of 9.80%[4] - The total profit for the period was CNY 76,887,856.58, showing a decrease of 13.00% compared to the same period last year[4] - The net profit attributable to shareholders was CNY 65,448,680.39, down 8.03% year-on-year[4] - The net profit after deducting non-recurring gains and losses was CNY 58,648,018.75, a decrease of 16.17% from the previous year[4] - The basic earnings per share for the period was CNY 0.16, a decrease of 11.11% year-on-year[4] - The weighted average return on equity was 1.61%, a decrease of 0.21 percentage points compared to the previous year[4] - The company achieved a total revenue of RMB 110,626.19 million for the first three quarters, representing a year-on-year growth of 2.12%[14] - The net profit attributable to shareholders for the same period was RMB 20,740.57 million, showing a year-on-year increase of 26.24%[14] - In Q3 alone, the company reported revenue of RMB 36,534.47 million, which is a 9.80% increase year-on-year, while net profit decreased by 8.03% to RMB 6,544.87 million[14] - Total operating revenue for the first three quarters of 2025 reached ¥1,106,261,911.75, an increase of 2.1% compared to ¥1,083,278,467.47 in the same period of 2024[22] - Net profit for the first three quarters of 2025 was ¥211,174,126.68, up 25.4% from ¥168,426,611.66 in the previous year[23] - Total comprehensive income amounted to CNY 211,174,126.68, an increase from CNY 168,426,611.66 in the previous period, representing a growth of approximately 25.4%[24] - Basic and diluted earnings per share increased to CNY 0.52 from CNY 0.41, reflecting a rise of 26.8%[24] Assets and Liabilities - The total assets at the end of the period amounted to CNY 5,093,265,583.29, reflecting a 2.94% increase from the end of the previous year[5] - The total assets of the company amounted to ¥5,093,265,583.29, compared to ¥4,948,035,237.87 in the previous period, indicating a growth of 2.9%[21] - The total liabilities increased to ¥1,006,444,803.73 from ¥984,785,361.90, marking a rise of 2.7%[20] - The equity attributable to shareholders rose to ¥4,073,322,439.44, up from ¥3,953,519,923.53, reflecting an increase of 3.0%[21] Cash Flow - The net cash flow from operating activities for the year-to-date was CNY 250,401,398.11, an increase of 31.90% compared to the previous year[4] - Net cash flow from operating activities was CNY 250,401,398.11, up from CNY 189,842,716.67, indicating a growth of 32%[28] - Cash inflow from investment activities totaled CNY 3,359,918,047.63, significantly higher than CNY 859,478,451.97 in the previous year[28] - Net cash flow from investment activities was negative at CNY -357,747,310.31, compared to CNY -5,178,898.97 previously, indicating increased investment outflows[28] - Cash and cash equivalents at the end of the period decreased to CNY 1,489,357,973.93 from CNY 1,924,464,930.46, a decline of approximately 22.6%[29] - Total cash outflow from financing activities was CNY 92,113,048.73, slightly higher than CNY 87,510,640.41 in the previous period[29] - The company received CNY 3,322,100,000.00 from the recovery of investments, a significant increase from CNY 840,000,000.00 in the prior year[28] - Cash received from other operating activities rose to CNY 57,891,432.49 from CNY 23,172,867.78, marking an increase of 149.5%[27] - The company reported a total cash inflow from operating activities of CNY 1,168,314,826.82, down from CNY 1,269,728,540.32, a decrease of approximately 8%[27] Research and Development - Research and development expenses totaled CNY 25,755,573.68, with a year-to-date decrease of 6.37%[5] - The ratio of R&D expenses to operating revenue was 7.05%, down 1.22 percentage points compared to the previous year[5] - Research and development expenses were ¥83,965,184.77, a decrease of 7.5% compared to ¥91,157,022.54 in the prior year[22] Sales and Marketing - The orthopedic product lines, particularly joint and spine minimally invasive products, showed significant growth, with joint product line sales revenue decreasing by 9% to RMB 27,322 million but with a 15% increase in volume[15] - The spine minimally invasive product line achieved a revenue growth of 3% year-on-year, with a 13% increase in sales volume[15] - The PRP product line generated approximately RMB 16,369 million in sales revenue, marking a 24% year-on-year increase, with a 23% increase in sales volume[16] - The company continues to optimize its sales model and enhance its marketing structure to improve clinical service levels and drive revenue growth[15] Cost Management - Total operating costs decreased to ¥863,391,351.16 from ¥909,362,061.83, representing a reduction of approximately 5.1%[22] - The company's gross profit margin improved, with operating profit increasing to ¥252,229,587.95 from ¥200,609,987.86, reflecting a growth of 25.7%[23] - The company reported a decrease in sales expenses to ¥292,240,112.98 from ¥371,892,305.06, a reduction of 21.4%[22]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：688161 证券简称：威高骨科 公告编号：2025-040 山东威高骨科材料股份有限公司 关于与私募基金合作投资公告 重要内容提示： 与私募基金合作投资的基本情况：山东威高骨科材料股份有限公司（以 下简称"公司"）拟与信金顺致私募基金管理（北京）有限公司、平湖鼎晟实业 有限公司、平湖市鑫翼东湖创业投资有限公司、浙江嘉创盛宇资产管理有限公司 共同投资设立嘉兴信威创盈股权投资合伙企业（有限合伙）（以下简称"合伙企 业"）（以市场监督管理机关最终核准登记为准）。合伙企业的认缴出资总额为 3 亿元，合伙企业的投资目标主要为医疗健康产业相关领域的处于成长期、成熟期 的企业/项目，与公司主营业务具有相关性。 相关风险提示 1、基金设立过程中存在可能因合伙人未能缴足认缴资金等客观原因，导致 基金未能成功募足资金的风险，实际募集及各方缴付出资情况可能存在不确定性。 投资金额、在投资基金中的占比及身份：公司作为有限合伙人，认缴出 资 6,000 万元，占合伙企业认缴出资总额的 20%。 ...

证券代码：688161 证券简称：威高骨科 公告编号：2025-041 山东威高骨科材料股份有限公司关于 拟聘请会计师事务所的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 变更会计师事务所的简要原因及前任会计师的异议情况：综合考虑公司 业务发展、审计工作需求等情况，为保证公司审计工作的独立性、客观性，公司 拟聘请德勤华永会计师事务所（特殊普通合伙）为公司 2025 年度财务报告和内 部控制审计机构。公司已就拟变更会计师事务所的相关情况与致同会计师事务所 （特殊普通合伙）进行充分沟通，其对变更事项无异议。 一、拟聘任会计师事务所的基本情况 （一）机构信息 1、基本信息 机构名称：德勤华永会计师事务所（特殊普通合伙） 成立日期：德勤华永会计师事务所（特殊普通合伙）的前身是1993年2月成 立的沪江德勤会计师事务所有限公司，于2002年更名为德勤华永会计师事务所有 限公司，于2012年9月经财政部等部门批准转制成为特殊普通合伙企业。 组织形式：特殊普通合伙 注册地址：上海市黄浦区延安东路222号30楼 首席 ...

证券代码：688161 证券简称：威高骨科 公告编号：2025-043 山东威高骨科材料股份有限公司 召开日期时间：2025 年 11 月 17 日 14 点 50 分 召开地点：山东威高骨科材料股份有限公司会议室（威海市旅游度假区香江 街 26 号） （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 11 月 17 日 至2025 年 11 月 17 日 关于召开2025年第二次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次 2025年第二次临时股东会 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 股东会召开日期：2025年11月17日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 （二） 股东会召集人：董事会 （三） 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 （四） 现场会议召开的日期、时间 ...

Industry Investment Rating - The report maintains an investment rating of "Outperform" for the orthopedic consumables sector [2]. Core Insights - The orthopedic consumables sector experienced significant performance improvement in H1 2025, with a positive trend in overseas expansion and accelerated corporate layouts [3][5]. - The overall revenue of the A-share orthopedic consumables sector increased by 16% year-on-year in H1 2025, with net profit attributable to shareholders rising by 70% and non-recurring net profit increasing by 75% [5][11]. - The gross profit margin for the sector was 66% in H1 2025, reflecting a year-on-year increase of 1.95 percentage points, attributed to ongoing cost control and optimization [5][11]. - The report highlights a favorable trend in overseas business, which is expected to become a significant growth driver for companies in the sector [5][35]. Summary by Sections 1. Orthopedic Consumables H1 2025 Report Analysis - The orthopedic consumables sector saw a revenue increase of 16.24% in H1 2025, with a gross profit margin of 66.07% [9][11]. - The second quarter of 2025 showed a revenue growth of 23% year-on-year, with net profit growth of 84% [11]. 2. Segment Analysis - The joint business segment benefited from the implementation of centralized procurement policies, leading to a sustained increase in both volume and price for leading companies [22]. - The spinal segment is experiencing stable execution of centralized procurement, with significant room for domestic companies to increase market share [29]. 3. Related Company Summaries - **Dabo Medical**: Achieved a revenue of 12.1 billion yuan in H1 2025, a year-on-year increase of 25.55%, with a net profit of 2.44 billion yuan, up 76.69% [41]. - **Weigao Orthopedics**: Reported a revenue of 7.41 billion yuan in H1 2025, a slight decrease of 1.28%, but net profit increased by 52.43% [57]. - **Aikang Medical**: Generated a revenue of 6.94 billion yuan in H1 2025, reflecting a growth of 5.65% year-on-year [47]. - **Chunli Medical**: Recorded a revenue of 4.88 billion yuan in H1 2025, up 28.27% year-on-year [52]. - **Sanyou Medical**: Achieved a revenue of 2.50 billion yuan in H1 2025, a year-on-year increase of 17.77% [61].

Core Viewpoint - The announcement details the implementation of the 2025 semi-annual profit distribution plan by Shandong Weigao Orthopedic Materials Co., Ltd, which includes a cash dividend of 0.10 yuan per share [1][4]. Distribution Plan - The distribution year is set for the 2025 semi-annual period [2]. - Eligible recipients include all shareholders registered with China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the close of trading on the registration date [2]. - The company has authorized the board to determine the specific distribution plan based on the conditions and limits approved at the 2024 annual shareholders' meeting [3]. Financial Details - The net profit attributable to shareholders for the first half of 2025 is reported at 141,957,058.61 yuan, with retained earnings amounting to 2,190,103,574.82 yuan [3]. - The cash flow from operating activities for the first half of 2025 is 186,207,847.40 yuan, indicating sufficient funds for normal operations and sustainable development [3]. - The total share capital is 400,000,000 shares, with 2,713,876 shares in the company's repurchase account excluded from the distribution, resulting in a distribution base of 397,286,124 shares [4]. Dividend Distribution - The company plans to distribute a cash dividend of 1.00 yuan for every 10 shares held, totaling 39,728,612.40 yuan, which represents 27.99% of the net profit attributable to shareholders for the first half of 2025 [4]. - The distribution will not involve capital reserve conversion to share capital or stock dividends [4]. Taxation Information - For individual shareholders holding unrestricted shares, dividends are subject to different tax treatments based on the holding period, with a maximum tax rate of 20% for shares held for less than one month [9][10]. - For foreign institutional investors, a 10% withholding tax applies to dividends received [11]. - The company will not withhold taxes for other institutional investors, who are responsible for their own tax declarations [12]. Implementation Method - The dividends will be distributed through China Securities Depository and Clearing Corporation Limited, with specific arrangements for shareholders who have designated trading [5][6]. - Shareholders who have not designated trading will have their dividends held until they complete the necessary procedures [5]. Contact Information - For inquiries regarding the distribution, shareholders can contact the company's securities affairs department at 0631-5788909 [13].

Group 1 - The core announcement from Weigao Orthopedics is the cash dividend distribution plan for the first half of 2025, which is set at 0.10 yuan per share (tax included) [2] - The record date for the dividend distribution is October 20, 2025, with the ex-dividend date and the cash dividend payment date both scheduled for October 21, 2025 [2]

北京市中伦（深圳）律师事务所 关于山东威高骨科材料股份有限公司 差异化分红的 法律意见书 致：山东威高骨科材料股份有限公司 北京市中伦（深圳）律师事务所（以下简称"本所"）接受山东威高骨科材 料股份有限公司（以下简称"公司"或"威高骨科"）的委托，根据《中华人民 共和国公司法（2023 修订）》（以下简称"《公司法》"）《中华人民共和国证券法 （2019 修订）》（以下简称"《证券法》"）《上市公司股份回购规则（2025 修订）》 （以下简称"《回购规则》"）、《上海证券交易所上市公司自律监管指引第 7 号— —回购股份（2025 年 3 月修订）》（以下简称"《回购指引》"）等有关法律、法 规、规范性文件和《山东威高骨科材料股份有限公司章程》（以下简称"《公司 章程》"）的规定，对威高骨科提供的有关文件进行了核查和验证，就公司 2025 年度中期权益分派的差异化分红（以下简称"本次差异化分红"）相关事宜出具 《北京市中伦（深圳）律师事务所关于山东威高骨科材料股份有限公司差异化分 红的法律意见书》（以下简称"本法律意见书"）。 就公司提供的文件、资料和陈述，本所及本所律师已得到公司的如下保证： 公司已经提供了 ...

1. 发放年度：2025年半年度 证券代码：688161 证券简称：威高骨科 公告编号：2025-039 山东威高骨科材料股份有限公司2025年半年度权益分派实施 公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/10/20 | 2025/10/21 | 2025/10/21 | 一、 通过分配方案的股东大会届次和日期 经公司 2025 年 4 月 21 日召开的 2024 年年度股东大会授权董事会在符合利润 分配的条件下制定具体的 2025 年中期分红方案，公司于 2025 年 8 月 26 日召开了 第三届董事会第十五次会议，第三届监事会第十三次会议，审议通过本次利润分 配方案。 二、 分配方案 （1）差异化分红方案 根据公司 2024 年年度股东大会审议通过的《关于授权董事会进行 2025 年度中 期分红的议案》，董事会在同时符合前提条件及金额上限的情况下根据届时情况制 定 2025 年度 ...